<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785510</url>
  </required_header>
  <id_info>
    <org_study_id>Egy Neuro 1 study</org_study_id>
    <nct_id>NCT02785510</nct_id>
  </id_info>
  <brief_title>Determining Clinical Profile of Parkinson's Disease Among Egyptian Population</brief_title>
  <official_title>Determining Clinical Profile of Parkinson's Disease Among Egyptian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease is the second most common neurodegenerative disease affecting about 1-3%
      of population above 60 years. Recently, non-motor symptoms are getting more attention in PD
      management. The pattern of PD onset and clinical course differ from one population to
      another. Many studies have been conducted to determine the clinical profile of PD in
      populations worldwide. However, no similar studies have been conducted in Egypt. Therefore,
      the investigators will conduct a nation-wide, collaborative, cross sectional study to
      determine the pattern of Parkinson's disease onset, clinical course, and non-motor symptoms
      among Egyptian population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age at disease onset</measure>
    <time_frame>At enrolment</time_frame>
    <description>Patients age when the initial symptom appeared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to diagnosis</measure>
    <time_frame>At enrolment</time_frame>
    <description>Duration, in years, from appearance of initial symptom to receiving Parkinson's disease diagnosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Initial motor symptom</measure>
    <time_frame>At enrolment</time_frame>
    <description>Number of patients with each initial motor symptom (tremor, rigidity, or bradykinesia).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Side of initial motor symptoms</measure>
    <time_frame>At enrolment</time_frame>
    <description>Number of patients with either right or left side initial motor symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical subtype of the disease</measure>
    <time_frame>At enrolment</time_frame>
    <description>Number patients with each disease subtype (tremor dominant Parkinson's disease, hypokinetic-rigid dominant Parkinson's disease, or postural instability and gait disturbance dominant Parkinson's disease).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of levodopa treatment from disease onset</measure>
    <time_frame>At enrolment</time_frame>
    <description>Number of years on levodopa treatment since receiving parkinson's disease diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levodopa equivalent dose</measure>
    <time_frame>At enrolment</time_frame>
    <description>Current dose of levodopa per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-motor symptoms</measure>
    <time_frame>At enrolment</time_frame>
    <description>Non-motor symptoms measured by the non-motor symptoms questionnaire (NMS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At enrolment</time_frame>
    <description>Mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort assessed by the parkinson's disease quality of life questionnaire (PDQ-39).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage of the disease [optional]</measure>
    <time_frame>At enrolment</time_frame>
    <description>The stage of the disease (stage 1, stage 2, stage 3, or stage 4) according to Hoehn and Yahr classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Functions [optional]</measure>
    <time_frame>At enrolment</time_frame>
    <description>Motor functions assessed by the third part of the unified parkinson's disease rating scale (UPDRS III).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Parkinson's Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who meet the diagnosis of Parkinson's disease according to the Parkinson's disease
        criteria of United Kingdom Brain Bank.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet the Parkinson's disease criteria of United Kingdom Brain Bank within
             the study centres.

        Exclusion Criteria:

          -  Patients with vascular Parkinsonism (history of stroke)

          -  Patients with treatment induced Parkinsonism

          -  Patients with history of dopaminergic neurotoxin
             (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed S Negida</last_name>
    <phone>+20 1125549087</phone>
    <email>ahmed01251@medicine.zu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Liver Institute</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samah A Loutfy, PhD</last_name>
      <email>samaly183@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://emra-collaborative.org/projects/neuro-1/index.html</url>
    <description>Study Website</description>
  </link>
  <reference>
    <citation>Obeso JA, Rodríguez-Oroz MC, Benitez-Temino B, Blesa FJ, Guridi J, Marin C, Rodriguez M. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord. 2008;23 Suppl 3:S548-59. doi: 10.1002/mds.22062. Review.</citation>
    <PMID>18781672</PMID>
  </reference>
  <reference>
    <citation>Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 4:S111-5. doi: 10.1016/S1353-8020(09)70847-8. Review.</citation>
    <PMID>20123548</PMID>
  </reference>
  <reference>
    <citation>Blin P, Dureau-Pournin C, Foubert-Samier A, Grolleau A, Corbillon E, Jové J, Lassalle R, Robinson P, Poutignat N, Droz-Perroteau C, Moore N. Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database. Eur J Neurol. 2015 Mar;22(3):464-71. doi: 10.1111/ene.12592. Epub 2014 Nov 12.</citation>
    <PMID>25389031</PMID>
  </reference>
  <reference>
    <citation>Durmus H, Gokalp MA, Hanagasi HA. Prevalence of Parkinson's disease in Baskale, Turkey: a population based study. Neurol Sci. 2015 Mar;36(3):411-3. doi: 10.1007/s10072-014-1988-x. Epub 2014 Oct 29.</citation>
    <PMID>25351343</PMID>
  </reference>
  <reference>
    <citation>Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 1;157(11):1015-22.</citation>
    <PMID>12777365</PMID>
  </reference>
  <reference>
    <citation>Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan;22(1):41-7.</citation>
    <PMID>17115387</PMID>
  </reference>
  <reference>
    <citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4.</citation>
    <PMID>1564476</PMID>
  </reference>
  <reference>
    <citation>Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):368-76. doi: 10.1136/jnnp.2007.131045. Review.</citation>
    <PMID>18344392</PMID>
  </reference>
  <reference>
    <citation>Liu WM, Wu RM, Lin JW, Liu YC, Chang CH, Lin CH. Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: A nationwide, population-based study. J Formos Med Assoc. 2016 Jul;115(7):531-8. doi: 10.1016/j.jfma.2015.05.014. Epub 2015 Jun 27.</citation>
    <PMID>26123636</PMID>
  </reference>
  <reference>
    <citation>Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583-90. doi: 10.1002/mds.25945. Epub 2014 Jun 28. Review.</citation>
    <PMID>24976103</PMID>
  </reference>
  <reference>
    <citation>Douglas MR. Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease. Expert Rev Neurother. 2013 Jun;13(6):695-705. doi: 10.1586/ern.13.58. Review.</citation>
    <PMID>23739006</PMID>
  </reference>
  <reference>
    <citation>Wang G, Li XJ, Hu YS, Cheng Q, Wang CF, Xiao Q, Liu J, Ma JF, Zhou HY, Pan J, Tan YY, Wang Y, Chen SD. Mortality from Parkinson's disease in China: Findings from a five-year follow up study in Shanghai. Can J Neurol Sci. 2015 Jul;42(4):242-7. doi: 10.1017/cjn.2015.49.</citation>
    <PMID>26153040</PMID>
  </reference>
  <reference>
    <citation>Wright Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143-51. doi: 10.1159/000275491. Epub 2010 Jan 15.</citation>
    <PMID>20090375</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>October 8, 2017</last_update_submitted>
  <last_update_submitted_qc>October 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Ahmed Negida</investigator_full_name>
    <investigator_title>(1) Principal Investigator; (2) Head of Scientific Committee, Student Research Unit, Zagazig University; and (3) Head of Scientific Committee, Egyptian National Research Collaborative.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be collected on a secure database (REDCap of Al-Azhar University). Investigators, who want to share a part of the whole of the patient data, should submit a request to our website (http://emra-collaborative.org/contact.html). They will enter in a data sharing agreement with the Egyptian National Research Collaborative to ensure proper acknowledgement of all study collaborators as non-author contributors in secondary publications from these data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

